Cargando…

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept

Detalles Bibliográficos
Autores principales:	Guermazi, Dorra, Arvanitis, Panos, Farmakiotis, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066965/ https://www.ncbi.nlm.nih.gov/pubmed/37004695 http://dx.doi.org/10.1007/s15010-023-02027-6

Ejemplares similares

508. Nirmatrelvir/ritonavir use among patients with cancer and COVID-19 is associated with improved clinical outcomes: Single-institution case-control study
por: Arvanitis, Panos, et al.
Publicado: (2023)

Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease
por: Dufour, Inès, et al.
Publicado: (2023)

Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
por: Arvanitis, Panos, et al.
Publicado: (2023)

Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
por: Arvanitis, Panos, et al.
Publicado: (2023)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

mRNA Vaccination Decreases COVID-19-Associated Morbidity and Mortality Among Organ Transplant Recipients: A Contemporary Cohort Study
por: Lerner, Alexis Hope, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

The unmet need for COVID-19 treatment in immunocompromised patients
por: Alessandra, D’Abramo, et al.
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
por: Rodionov, Roman N, et al.
Publicado: (2021)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

Digital ultraviolet B phototherapy in vitiligo: proof of concept
por: Graier, T., et al.
Publicado: (2019)

631. Using a commercially available assay that measures cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity to predict protection against CMV: Results from a prospective, blinded clinical trial
por: Almaghlouth, Nouf K, et al.
Publicado: (2023)

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
por: Mali, Kalpana Ramanna, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
por: Alteri, Claudia, et al.
Publicado: (2022)

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
por: Johnson, Matthew G., et al.
Publicado: (2023)

528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)

Rat Hepatitis E in an Immunocompromised Patient
por: Hon, Kam Lun, et al.
Publicado: (2020)

Challenges in Antimicrobial Stewardship: Rapid Diagnostics and Optimization of Therapy Among Immunocompromised Patients
por: Rosa, Rossana, et al.
Publicado: (2019)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review
por: Parker, Edward P K, et al.
Publicado: (2022)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

An Opportunity to Better Understand the Impact of Coronaviruses on Immunocompromised Patients
por: Parisi, Christina
Publicado: (2020)

Rapid-CNS(2): rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study
por: Patel, Areeba, et al.
Publicado: (2022)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients
por: Scherer, Erin M., et al.
Publicado: (2022)

Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
por: Benaicha, Karima, et al.
Publicado: (2023)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

PANORAMIC: important insights into molnupiravir use in COVID-19
por: Kidd, Michael R, et al.
Publicado: (2023)

COVID-19 Among Liver Transplant Recipients
por: Moris, Dimitrios
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lqm7limc2r25btqdcm11giu97q